Women being treated for osteoporosis expressed an overwhelming preference for monthly dosing over weekly dosing in a recent nationwide survey. The study, directed by Wulf Utian of The Cleveland Clinic in Cleveland, OH, supports the monthly dosing schedule offered by ibandronate, a competing oral bisphosphonate.
Phase II studies have shown that lasofoxifene, a next-generation selective estrogen-receptor modulator, increased bone mineral density and improved both objective measures of vaginal atrophy and reported symptoms. Margery Gass, MD, and a team from the University of Cincinnati Medical Center reported yesterday that a double-blind, randomized, placebo-controlled Phase III trial produced similar results.
Dyspareunia is a significant problem in postmenopausal women. A recent study at George Washington University found that up to 92% of sexually active women reported moderate or severe symptoms. Forty percent of women cited dyspareunia as their most bothersome problem associated with vaginal atrophy. A recent Phase III trial showed that lasofoxifene can significantly improve the symptoms of dyspareunia as well as increase bone mineral density (BMD) in postmenopausal women.
An expert shares ways to avoid misdiagnosing vulvovaginal infections by becoming better acquainted with the microscopy of vaginal secretions, routinely using both pH paper and the amine test, and prudently employing vaginal yeast and Trichomonas cultures.
The ability to obtain emergency contraception (EC) directly from a pharmacist does not mean women would be more inclined to use it than if they only had access through a clinic, according to a randomized, controlled trial of over 2,000 women.
Charting tops the list, according to an informal survey conducted by Medical Economics (12/17/04).
PMS has been a legitimate diagnosis for several decades, but there are no FDA-approved therapies for it. Off-label use of medications that are FDA-approved for PMDD is common in clinical practice. For patients taking daily SSRIs for anxiety or mood symptoms, premenstrual dose adjustment offers a novel management strategy.